Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO

In a world where healthcare innovation is accelerating, companies leveraging artificial intelligence are leading the charge in transforming patient care, diagnostics, and therapeutic solutions. Their advancements in smart disinfection, AI-designed therapies, precision gene editing, and cardiovascular diagnostics are not only reshaping their industries but also unlocking tremendous growth potential. Here's how these cutting-edge companies are redefining the future of healthcare.

CS Diagnostics Corp. (OTCQB: CSDX) Launches Next-Gen Disinfectant MEDUSA a cutting-edge smart disinfectant approved in the EU and UAE, with U.S. approval pending. Offering up to 10 days of surface protection in alcohol-free and alcohol-based formulations, MEDUSA targets both B2B and B2C markets. The company projects $80 million in revenue by 2025 and aims to capture 10% of the $8.37 billion global disinfectant market. Negotiations with a leading European football club could further expand its global reach.

ImmunoPrecise Antibodies (NASDAQ: IPA) Introduces AI-Designed GLP-1 Therapiesfor type 2 diabetes and obesity using its proprietary LENS ai™ platform. These treatments improve stability, reduce dosing, and may offer non-invasive delivery options. As IPA’s first fully AI-generated assets, they represent a breakthrough in diabetes treatment and patient care innovation.

Metagenomi (NASDAQ: MGX) Announces Key 2025 Milestones and highlighted progress in its genetic medicine pipeline, including advancing MGX-001 for Hemophilia A and proof-of-concept work for protein deficiency treatment. The company plans to nominate up to two cardiometabolic candidates in collaboration with Ionis by 2025 and is funded through 2027. CEO Brian C. Thomas emphasized its focus on transformative therapies.

Cardio Diagnostics (NASDAQ: CDIO) Gains Medicare Pricing for its AI-powered PrecisionCHD and Epi+Gen CHD tests, effective January 1, 2025. These tests use genetic and epigenetic markers to improve coronary heart disease (CHD) diagnosis and risk assessment, addressing a top cause of U.S. mortality. CEO Dr. Meesha Dogan called it a major step in personalized cardiovascular care.

These advancements position CSDX, IPA, MGX, and CDIO as innovators in healthcare and medical AI, paving the way for significant growth opportunities in their respective markets.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.